title: Neuromodulatory and anti-inflammatory ingredient for sensitive skin: in vitro assessment.
abstract: The manifestation of sensitive skin occurs as a consequence of increased permeability of the Stratum corneum, besides the involvement of neuro-immune-endocrine system. In this study, we evaluated the effects of an active ingredient SensC on the production of neuropeptides substance P (SP), enkephalin and β-endorphin; eicosanoids prostaglandin E2 (PGE2) and leukotriene B4 (LTB4); histamine, transient receptor potential vanilloid subfamily member 1 (TRPV1), and envelope proteins filaggrin and involucrin, using an in vitro model of human cell culture. Our results demonstrated that treatment of keratinocyte cultures with SensC prevented the increase of all evaluated inflammatory mediators induced by interleukin-1 alpha (IL-1α). As the same way, SensC provides decrease in the synthesis of TRPV1. Regarding the synthesis of envelope proteins, SensC promoted increases for filaggrin and involucrin levels, when compared to control group. Considering the absence of appropriate treatment, the availability of ingredients, such as SensC, with antiinflammatory and protective barrier properties can be a significant tool for preventing neurosensorial symptoms associated with sensitive skin.
authors.forename: Adilson
authors.initials: A
authors.lastname: Costa
authors.forename: Samara
authors.initials: S
authors.lastname: Eberlin
authors.forename: Anelise J
authors.initials: AJ
authors.lastname: Polettini
authors.forename: Andreia F
authors.initials: AF
authors.lastname: da Costa Pereira
authors.forename: Caroline S
authors.initials: CS
authors.lastname: Pereira
authors.forename: Nayara M Cortes
authors.initials: NM
authors.lastname: Ferreira
authors.forename: Eleonora
authors.initials: E
authors.lastname: Dolis
authors.affiliation: KOLderma Clinical Trials Institute, Campinas/SP, Brazil. adilson_costa@hotmail.com.
authors.forename: Liliana B Oliveira
authors.initials: LB
authors.lastname: Torloni
mesh_terms: D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D003879:Dermatologic Agents / Q000494:pharmacology; D015777:Eicosanoids / Q000378:metabolism; D000091344:Filaggrin Proteins; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018836:Inflammation Mediators / Q000378:metabolism; D015603:Keratinocytes / Q000187:drug effects* / Q000276:immunology; D008297:Male; D009479:Neuropeptides / Q000378:metabolism; D012867:Skin / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D050916:TRPV Cation Channels / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D015777:Eicosanoids; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D018836:Inflammation Mediators; D009479:Neuropeptides; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human